Skip to main content

Table 3 Overall tophus complete response in patients over time during the randomized controlled trials a

From: Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Variables

Pegloticase

Pegloticase

Placebo

 

biweekly

monthly

 

(n= 62)

(n= 64)

(n= 29)

Week 13

 Patients with evaluable tophi at visit, n

46

48

25

 CR, n (%)

10 (22)

4 (8)

0

P valueb

0.011

0.292

Week 25

 Patients with evaluable tophi at visit, n

40

39

24

 CR, n (%)

18 (45)

10 (26)

2 (8)

P valueb

0.002

0.110

Final visitc

 Patients with evaluable tophi, n

52

52

27

 CR, n (%)

21 (40)

11 (21)

2 (7)

P valueb

0.002

0.200

  1. aCR, complete response. bPegloticase groups versus placebo for CR. cFinal visit includes data from the patient’s final visit, whenever it occurred, for all evaluable completers and noncompleters.